1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3. The Global Ophthalmic Drugs Market, 2015-2025
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation Of The Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2014
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2015-2025
3.5 Ophthalmic Drugs: Changing Market Shares By Sector 2015-2025
4. The Retinal Disorder Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Leading Products In The Retinal Disorder Drugs Market, 2014
4.2 Retinal Disorders: Market Trends And Developments, 2015
4.2.1 The Rise And Rise Of Lucentis
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales And ThromboGenics’ Efforts To Reverse It
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2015-2025
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Lucentis (ranibizumab) – Roche/ Novartis
4.5.1 Lucentis: Sales Forecast 2015-2025
4.5.2 Less Frequent Dosing Approved In US For Lucentis
4.5.3 New Indications For Lucentis
4.5.4 Possible Combination Therapy Involving Lucentis
4.6 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.6.1 Recent Approvals For Eylea
4.6.2 Eylea: Sales Forecast 2015-2025
4.6.3 Possible Combination Therapies Involving Eylea
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2015-2025
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2015-2025
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2015-2025
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2015-2025
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2014
5.1.1 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2015
5.1.2 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.1.3 Topical NSAIDs Launched: Prolensa and Ilevro
5.2 Allergic, Inflammatory And Infective Drugs: Market Forecast 2015-2025
5.2.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.4 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.4.1 Pataday: Sales Forecast 2015-2025
5.4.2 Impending Generic Competition For Patanol And Pataday
5.4.3 Approval Of Pazeo Solution
5.4.4 Patanol: Sales Forecast 2015-2025
5.5 Vigamox (moxifloxacin) – Alcon (Novartis)
5.5.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.5.2 Moxeza: A Next-Generation Form of Vigamox
5.5.3 Vigamox: Sales Forecast 2015-2025
5.6 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.6.1 The Development And Commercialisation Of TobraDex ST
5.6.2 TobraDex: Sales Forecast 2015-2025
5.7 Bromday (bromfenac) – Valeant
5.7.1 Prolensa: A New Formulation Of Bromfenac
5.7.2 Competition From Ilevro/Nevanac
5.7.3 Bromday: Sales Forecast 2015-2025
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2015-2025
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2015-2025
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2015-2025
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2015-2025
6. Glaucoma Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2014
6.2 Glaucoma Drugs: Market Trends And Developments, 2015
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.2.4 Simbrinza: First Beta-Blocker-Free Combination
6.3 Glaucoma Drugs: Market Forecast 2015-2025
6.3.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs For The Treatment Of Glaucoma
6.5 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.5.1 Lumigan And Ganfort: Sales Forecast 2015-2025
6.6 Xalatan And Xalacom (latanoprost) – Pfizer
6.6.1 Xalatan/Xalacom: Sales Forecast 2015-2025
6.7 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.7.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2015-2025
6.8 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.8.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2015-2025
6.9 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.9.1 Divestment Agreement With Santen And Akorn
6.9.2 Trusopt: Sales Forecast 2015-2025
6.9.3 Cosopt And Cosopt PF: Sales Forecast 2015-2025
6.10 Azopt (brinzolamide) – Novartis
6.10.1 Azopt: Sales Forecast 2015-2025
6.11 Tapros (tafluprost) – Santen
6.11.1 Tapros: Sales Forecast 2015-2025
6.12 Zioptan (tafluprost) – Akorn
6.12.1 Zioptan: Sales Forecast 2015-2025
6.13 Other Glaucoma Drugs: Sales Forecast 2015-2025
7. Dry Eye Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2014
7.2 Dry Eye Drugs: Market Trends And Developments, 2015
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2015-2025
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis Patent Elongation
7.5.2 Restasis: Sales Forecast 2015-2025
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2015-2025
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2015-2025
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2015-2025
7.9 Other Dry Eye Drugs: Sales Forecast 2015-2025
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.1.1 Hetlioz: Sales Forecast 2015-2025
8. Leading National Markets For Ophthalmic Drugs, 2015-2025
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2015-2025
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.11 Mexico
8.11.1 Mexican Healthcare Reform: Introducing Seguro Popular
8.11.2 Are Multinationals Waking Up To Mexico’s Market Potential?
8.11.3 Mexican Ophthalmic Drugs Market: Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2015-2025
9. Leading Companies In The Ophthalmic Drugs Market, 2015-2025
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.1.1 Leading Companies In The Ophthalmic Drugs Market, 2015
9.1.2 Ophthalmic Drugs Market: Leading Companies Forecast 2015-2025
9.1.3 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2015-2025
9.2 Novartis (Alcon)
9.2.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.2.2 Novartis: Sales Forecast 2015-2025
9.2.3 Novartis: Ophthalmic Drugs Development Pipeline, 2015
9.2.4 Novartis: Recent Developments
9.2.4.1 Novartis Restructures Following Strategic Review
9.2.4.2 Novartis Licenses Ophthotech’s Fovista
9.3 Allergan (Actavis)
9.3.1 Allergan: Ophthalmic Drugs Portfolio
9.3.2 Allergan: Recent Developments
9.3.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.3.2.2 How Real Is The Threat Of Generic Restasis?
9.3.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.3.3 Allergan: Sales Forecast 2015-2025
9.3.4 Allergan: Ophthalmic Drugs Development Pipeline, 2015
9.4 Roche
9.4.1 Roche: Ophthalmic Drugs Portfolio, 2015
9.4.1.1 Lucentis: US Sales Forecast 2015-2025
9.4.2 Roche: Sales Forecast 2015-2025
9.4.3 Roche: Ophthalmic Drugs Development Pipeline, 2015
9.5 Santen
9.5.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.5.2 Santen: Recent Developments
9.5.2.1 Santen Acquires Novagali Pharma
9.5.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.5.3 Santen: Sales Forecast 2015-2025
9.5.4 Santen: Ophthalmic Drugs Development Pipeline, 2015
9.6 Regeneron
9.6.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.6.2 Regeneron: Recent Developments
9.6.2.1 Expanding Indications For Eylea
9.6.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.6.3 Regeneron: Sales Forecast 2015-2025
9.6.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2015-2025
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2015
9.8 Pfizer
9.8.1 Pfizer: Ophthalmic Drugs Portfolio, 2015
9.8.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.8.1.2 Macugen – Valeant/Pfizer
9.8.2 Pfizer: Recent Developments
9.8.2.1 Pfizer Attempts to Acquire AstraZeneca
9.8.3 Pfizer: Sales Forecast 2015-2025
9.8.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2015
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2015-2025
9.10 Senju
9.10.1 Senju: Ophthalmic Drugs Portfolio
9.10.2 Senju: Sales Forecast 2015-2025
9.10.3 Senju: Ophthalmic Drugs Development Pipeline, 2015
9.10.3.1 Y 39983 (SNJ 1656)
9.10.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research And Development Pipeline, 2015-2025
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2015
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.2.2 Retinal Disorders: Filed or Recently Launched
10.2.2.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.2.2.2 Lipidil (fenofibrate) – Abbott
10.2.2.3 Iluvien (fluocinolone) – Alimera Sciences
10.2.3 Drugs In Phase 3 Development For Retinal Disorders
10.2.3.1 Fovista and Zimura – Ophthotech Corporation
10.2.3.2 Lampalizumab (anti-Factor D Fab) – Roche
10.2.3.3 MC-1101 (hydralazine) – MacuCLEAR
10.2.3.4 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.2.3.5 UF-021 (unoprostone) – R-Tech Ueno
10.2.4 Drugs In Phase 2 Development For Retinal Disorders
10.2.4.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.2.4.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.2.4.3 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.2.4.4 AGN208397 (beclomethasone) – Allergan
10.2.4.5 CPC 551 – Colby Pharmaceutical
10.2.4.6 Darapladib And GSK933776 – GlaxoSmithKline
10.2.4.7 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.2.4.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.2.4.9 iSONEP (sonepcizumab) – Lpath
10.2.4.10 LFG316 (anti-C5 mAb) – Novartis
10.2.4.11 Novadur (Intravitreal brimonidine implant) – Allergan
10.2.4.12 Optina (danazol) – Ampio Pharmaceuticals
10.2.4.13 PF-655 (synthetic siRNA) – Quark/Pfizer
10.2.4.14 Premiplex (protein replacement therapy) – Shire
10.2.4.15 Renexus (ciliary neurotrophic factor) – Neurotech
10.2.4.16 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.2.4.17 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.2.5 Drugs In Phase 1 And Pre-clinical Development For Retinal Disorders
10.2.5.1 BDM-E – BioDiem
10.2.5.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.2.5.3 NS2 (aldehyde trap) – Aldeyra Therapeutics
10.2.5.4 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.2.5.5 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.2.5.6 QLT091001 (synthetic retinoid) – QLT
10.3 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.1.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.3.1.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.3.1.3 LE-MPP (loteprednol etabonate) – Kala
10.3.2 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.2.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.3.2.2 FST-100 (povidone-iodine/dexamethasone) – ForeSight Biotherapeutics
10.3.2.3 NVC-422 (auriclosene) – NovaBay
10.3.2.4 Sarilumab – Regeneron
10.3.2.5 V404 PDS – ForSight VISION
10.3.3 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.3.3.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.4 Drugs For Glaucoma: Development Pipeline, 2015
10.4.1 Drugs In Phase 2&3 Development For Glaucoma
10.4.1.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.4.1.2 AMA0076 (ROCK inhibitor) – Amakem
10.4.1.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.4.2 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.5 Drugs For Dry Eye: Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dry Eye
10.5.1.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.5.1.2 Lifitegrast (integrin antagonist) – Shire
10.5.1.3 MIM-D3 (tyrosine kinase receptor antagonist) – Valeant
10.5.1.4 SI-614 (modified hyaluronate) – Seikagaku
10.5.2 Drugs In Phase 2 Development For Dry Eye
10.5.2.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.5.2.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.6 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.6.1 Brimonidine For Eye Whitening – Valeant
10.6.2 GS-101 (aganirsen) – Gene Signal
10.6.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2015-2025
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 A Healthy R&D Pipeline
11.2.1.2 Advances In Drug Delivery Technologies
11.2.1.3 Support For Reimbursement And Payment Approvals
11.2.1.4 Gene Therapy And RNA Interference Technology
11.2.1.5 New Ophthalmic Therapeutic Applications For Drugs
11.2.1.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.2.1.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.2.2 Weaknesses
11.2.2.1 Patient Adherence To Treatment
11.2.2.2 High Treatment Burden On Patients And Healthcare Providers
11.2.2.3 Under-Diagnosis And Under-Treatment
11.2.3 Opportunities
11.2.3.1 Sustained-Release Ocular Implants
11.2.3.2 The Impact Of A Rapidly Ageing Global Population
11.2.3.3 Increasing Prevalence Of Eye Diseases And Diabetes
11.2.3.4 Glaucoma And Retinal Disorders Will Have the Most-Marked Increases In Prevalence
11.2.3.5 Unmet Clinical Need In Many Disease Areas
11.2.3.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.2.4 Threats
11.2.4.1 Intensifying Price Regulation In The Market
11.2.4.2 Generic Competition – Likely Erosion Of Sales For Market Leading Brands
11.2.4.3 Rising Costs Of R&D
11.2.4.4 Biosimilars – A Potent Threat To Ophthalmic Drugs’ Success
11.3 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.3.1 Threat of New Entrants
11.3.2 Rivalry Among Competitors
11.3.3 Power of Suppliers
11.3.4 Threat of Substitutes
11.3.5 Power of Buyers
12. Expert Opinions from Our Primary Research
12.1 Interview with Dr Patrik De Haes, CEO and Mr Wouter Piepers, Global Head Of Corporate Communications & Investor Relations At ThromboGenics nv
12.1.1 The Ophthalmic Drug Segments Presenting Growth Opportunities
12.1.2 Jetrea As A Game-Changer In The Treatment Of Vitreomacular Adhesion
12.1.3 The Need To Embrace Novel Treatments
12.1.4 Future Plans For Jetrea
12.1.5 Expanding Treatment Indications And Strategies For Maximising Product Potential
12.1.6 Will Jetrea Be A Substitute For Surgery In Vitreomacular Adhesion Patients?
12.1.7 Development Efforts For Jetrea In Retinal Vein Occlusion
12.1.8 Future Prospects For The Ophthalmic Drugs Market
12.2 Interview With A Spokesperson From Akorn Pharmaceuticals
12.2.1 New Formulation Strategies For Cosopt, Zioptan And Azasite
12.2.2 Expansion Plans For Akorn’s Ophthalmic Portfolio
12.2.3 Tackling Key Unmet Needs Within Ophthalmics
12.2.4 Akorn’s Future Plans For Growth
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Ophthalmic Drugs In 2014
13.3 Leading Regions In The Ophthalmic Drugs Market In 2014
13.4 Leading Companies In The Ophthalmic Drugs Market, 2014
13.5 What Does The Future Hold For Ophthalmic Drugs?
Table 1.1 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2014-2025 (Redacted Data)
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments For Glaucoma, 2015
Table 2.3 Drug Treatments For Age-Related Macular Degeneration, 2015
Table 2.4 Drug Treatments For Ocular Allergy, 2015
Table 2.5 Drug Treatments For Ocular Inflammatory Disease, 2015
Table 2.6 Drug Treatments For Eye Infections, 2015
Table 2.7 Clinical Trial Phases, 2015
Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2014-2025
Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
Table 3.4 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
Table 4.1 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2014
Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 4.4 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.5 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.1 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2014
Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.8 Bromday: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.9 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.10 Acular: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.11 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.12 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2014
Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2014
Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2014-2025
Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.7 The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
Table 8.8 The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2014
Table 8.9 The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.10 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
Table 8.11 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.12 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.13 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.14 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.15 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.16 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.17 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.18 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.19 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.21 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.22 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.23 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.24 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.25 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.26 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.27 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.28 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.29 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.30 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.31 The Mexican Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.32 The Mexican Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.33 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.34 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2014
Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2014-2025
Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2014, 2019, 2025
Table 9.4 Novartis: Company Overview, 2015
Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.6 Allergan: Company Overview, 2015
Table 9.7 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.8 Roche: Company Overview, 2015
Table 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.11 Santen: Company Overview, 2015
Table 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.13 Regeneron: Company Overview, 2015
Table 9.14 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.15 Valeant: Company Overview, 2015
Table 9.16 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.17 Pfizer: Company Overview, 2015
Table 9.18 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.19 Bayer: Company Overview, 2015
Table 9.20 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.21 Senju: Company Overview, 2015
Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 10.1 Retinal Disorders Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.3 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
Table 10.4 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
Table 10.7 Glaucoma Drugs Pipeline: Phase 2&3 Drugs, 2015
Table 10.8 Glaucoma Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
Table 10.9 Dry Eye Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.10 Dry Eye Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.11 Other Pipeline Products for Ophthalmic Conditions, 2015
Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2015-2025
Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2025
Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases from 2014
Table 13.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
Table 13.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025
List of Figures
Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2015
Figure 1.2 Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Altered Data)
Figure 2.1 Structure Of The Human Eye
Figure 2.2 Estimated Global Prevalence Of Visual Impairment (millions of people), 2014
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.4 Classification Of Glaucoma, 2015
Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2014
Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2014-2019
Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2019-2025
Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2014-2025
Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2014
Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2019
Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2025
Figure 4.1 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m), 2014
Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2014-2025
Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 4.7 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2014-2025
Figure 4.8 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2014-2025
Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2014-2025
Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2014-2025
Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2014-2025
Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.1 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2014
Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2014-2025
Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2014-2025
Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2014-2025
Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.11 Bromday: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.12 Cravit: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.13 Acular: Sales Forecast ($m, AGR%), 2014-2025
Figure 5.14 AzaSite: Akorn Sales Forecast ($m, AGR%), 2014-2025
Figure 5.15 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2014
Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2014-2025
Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2014-2025
Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2014-2025
Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2014-2025
Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2014-2025
Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2014
Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2014
Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2019
Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2025
Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2014-2025
Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2014-2025
Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2014-2025
Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2014-2025
Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2014-2025
Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2014
Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.3 Brazil, Russia, India, and Mexico Ophthalmic Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2014-2019
Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2019-2025
Figure 8.6 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2014-2025
Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2014
Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2019
Figure 8.9 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2025
Figure 8.10 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.11 The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2014
Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.13 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2014
Figure 8.14 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2019
Figure 8.15 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2025
Figure 8.16 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.18 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.19 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.21 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.22 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.23 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.24 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.25 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.26 The Mexican Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.27 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2014
Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%) by Leading Companies, 2014-2025
Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2014
Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2019
Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2025
Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.7 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.8 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.9 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.10 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.11 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.12 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.13 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.14 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2014-2025
Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
Figure 11.3 Porter’s Five Force Analysis of the Ophthalmic Drugs Market, 2015
Figure 13.1 Global Ophthalmic Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025
Figure 13.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2014-2025
【レポートのキーワード】
眼科用薬、ドライアイ治療薬、緑内障治療薬、網膜障害治療薬、アレルギー性・炎症性・感染性眼科疾患治療薬、目薬
